OncoMatch

OncoMatch/Clinical Trials/NCT07319871

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

Is NCT07319871 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pasritamig and JNJ-86974680 for prostatic neoplasms.

Phase 1RecruitingJanssen Research & Development, LLCNCT07319871Data as of May 2026

Treatment: Pasritamig · JNJ-86974680The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Biomarker criteria

Required: KLK3 PSA ≥ 2 ng/mL (≥ 2 ng/mL)

Prostate-specific antigen (PSA) greater than or equal to (≥) 2 nanograms per milliliters (ng/mL) at screening

Disease stage

Required: Stage METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Metastatic disease required

Metastatic castration-resistant prostate cancer (mCRPC) that is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs. Local-regional invasion (rectum, bladder) and bone disease with soft tissue component can be included

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: androgen deprivation therapy (orchiectomy, gonadotropin-releasing hormone (GnRH) analog (agonist or antagonist)) — ongoing

Prior orchiectomy or medical castration (for example, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone [GnRH] analog [agonist or antagonist] prior to the first dose of study drug and must continue this therapy throughout the treatment phase)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Florida Cancer Specialists · Sarasota, Florida
  • Columbia University Medical Center · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify